NEW YORK (GenomeWeb) – The National Cancer Institute and its Children’s Oncology Group (COG) announced today that they have begun enrollment in a Phase II trial that will test a variety of targeted treatments for childhood cancers.
Called Pediatric MATCH — short for Molecular Analysis for Therapy Choice — the study has been in the works since 2015 as the pediatric counterpart to an ongoing precision medicine study in cancer patients 18 years and older. The NCI’s plans for Pediatric MATCH were first reported last year.
The trial will initially comprise six treatment arms with one targeted drug being evaluated in each, although the number of arms may be expanded to eight or more as the study progresses. Enrollment will be open to patients aged one to 21 with certain solid tumors — including non-Hodgkin lymphomas, brain tumors, and histiocytoses — that no longer respond to standard treatment or have recurred after treatment.
All patients will initially have their relapsed tumors sequenced using an NCI-developed test to detect genetic abnormalities targeted by one or more of the drugs being studied. Archived tumor samples may be used if they were obtained after the tumor progressed following initial treatment, the NCI noted.